Feb. 13 at 2:13 PM
$DTIL has announced that the FDA has granted a Study May Proceed notification, allowing initiation of clinical trial site activation for the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD in ambulatory Duchenne muscular dystrophy (DMD) patients at specialized clinical sites
https://biotuesdays.com/2026/02/13/fda-clears-precisions-ind-for-pbgene-dmd/